Reason: CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 100 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.
Distributed: Nationwide.Reason: CGMP Deviations: Ethambutol Hydrochloride Tablets, USP, 400 mg were manufactured using unapproved material: the incorrect gelatin excipient than specified in the product formulation.
Distributed: Nationwide.Reason: Failed Dissolution Specifications: Product did not meet specification requirements for dissolution.
Distributed: NationwideReason: Presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.
Distributed: Nationwide including Puerto Rico.Reason: Presence of Foreign Tablet; customer complaint of some tablets of Gabapentin found in a bottle of Metformin HCl ER
Distributed: NationwideReason: Subpotent Drug: Drug potency was compromised during shipment.
Distributed: Distributed nationwide to physicians as samples. No military/ govt/ VA or foreign consignees.Reason: Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.
Distributed: NationwideReason: Presence of Foreign Tablets: A product complaint was received by a pharmacist who discovered an Atorvastatin 20 mg tablet inside a sealed bottle of 90-count Atorvastatin 10 mg.
Distributed: NationwideReason: Labeling: Label Error On Declared Strength: Trelstar 11.25 mg labeled carton/kit contained a vial labeled as 3.75 mg instead of a vial being labeled as 11.25mg.
Distributed: Nationwide and Puerto RicoReason: Subpotent Drug: Assay results obtained during stability testing for Levothyroxine Sodium Tablets, USP were below specification.
Distributed: Nationwide.